Genetic susceptibility to XXXX .

@entity172 @entity19 @entity2659 @entity5132 @entity53 @entity7553 @entity365 @entity7840
To enable future studies on host resistance factors and therapy, inbred and outbred @entity19 strains were tested for susceptibility to @entity365 . Groups of @entity19 were given 0.5 mg @entity53 3 days before and 4 days after intravaginal challenge with a suspension of @entity5132 . On day 1 after challenge, a swab was used to quantitate infection in all groups and to assure equivalent infection levels. On day 6, this was repeated and the experiment was terminated. BALB/c, the reference strain in repeated experiments, was susceptible, showing persistent infection with levels of cfu at day 6 falling within a range between a twofold decrease and a fourfold increase in relation to day 1 levels. @entity2659 outbred @entity19 were markedly resistant, with day 6 cfu levels showing a 74- to 87-fold decrease with respect to day 1 levels, whereas other outbred strains (CF-1, SW, ICR) were susceptible. A BALB/c substrain (ByJ) was also susceptible. With exception of CBA/J, which showed modest resistance, all inbred strains were similarly susceptible, including @entity7840 /2, AKR/J, C3H/HeN, A/J and C57BL/6. The differences between @entity2659 /c @entity19 were also seen with a second @entity5132 isolate. Our results show susceptibility to @entity365 is independent of the major histocompatibility locus H2 haplotype and any effect ascribable to use of particular commercial @entity19 suppliers. Differences among @entity19 strains in susceptibility to @entity5132 , as seen in previous studies involving nonvaginal challenge routes, are not reflected in this @entity365 model; in general, such resistance patterns appear specific to the route of challenge administration. The resistance seen in @entity19 @entity2659 is of particular interest in that @entity2659 is known to be resistant to endocrine disruption by @entity172 . Our results suggest this @entity172 insensitivity may have broad-ranging effects on processes other than gametogenesis, including vaginal susceptibility to @entity7553 .
